SCHEMBL6992017

SCHEMBL6992017

CC1Oc2ccc(CNCc3cccnc3)cc2NC1=O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 6/20 0.75
HSD17B10 Q99714 2/20 0.56
MAPT P10636 1/20 0.56
TSHR P16473 1/20 0.56
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
ALDH1A1 P00352 6/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PDGFRB P09619 1/20 0.45
KDR P35968 1/20 0.45
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
LTA4H P09960 1/20 0.43
ROCK2 O75116 1/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 1/20 0.41
PDE3B Q13370 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6305288 0.87 PARP1 (0.88) PARP1HSD17B10MAPTTSHRTP53
SCHEMBL6989623 0.86 PARP1 (0.78) PARP1HSD17B10MAPTTSHRROCK2
SCHEMBL532477 0.86 PARP1 (1.00) PARP1HSD17B10ALOX15TP53POLB
SCHEMBL6302991 0.86 PARP1 (0.90) PARP1TP53POLBPDE3BPDE3A
SCHEMBL6310170 0.84 PARP1 (0.95) PARP1HSD17B10ALOX15TP53POLB
SCHEMBL532908 0.83 PARP1 (0.55) PARP1HSD17B10MAPTTSHRALDH1A1
SCHEMBL6302733 0.82 PARP1 (0.78) PARP1HSD17B10MAPTTSHRTP53
SCHEMBL7000091 0.82 PARP1 (0.78) PARP1PDGFRBKDRTP53PDE3B
SCHEMBL6996295 0.82 PARP1 (0.78) PARP1HSD17B10PDGFRBKDRTP53
SCHEMBL7003151 0.81 PARP1 (0.81) PARP1TSHRTP53POLBPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed